21 May 2013 - Biotechnology company Acorda Therapeutics Inc (NasdaqGS:ACOR) reported on Monday the receipt of a patent for its US Patent Application No. 8,440,703 (the '703 patent) entitled "Methods of Using Sustained Release Aminopyridine Compositions".

This patent was awarded by the United States Patent and Trademark Office (USPTO).

The company said that the '703 patent includes claims directed to methods of improving lower extremity function and walking and increasing walking speed in patients with multiple sclerosis (MS) by administering less than 15 mg of sustained release 4-aminopyridine (dalfampridine) twice daily.

According to the company, AMPYRA is approved in the US as a treatment to improve walking in patients with multiple sclerosis (MS). AMPYRA is known as prolonged-, modified-, or sustained-release fampridine (FAMPYRA) in some countries outside the US.

In addition, the company's '703 patent is set to expire in 2025 and this patent is eligible for listing in the US Food and Drug Administration (FDA) Orange Book.